SMTL ID : 7c3n.1

Crystal structure of JAK3 in complex with Delgocitinib

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 1.98 Å

Oligo State

monomer

Ligands

1 x FHX: 3-[(3S,4R)-3-methyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,7-diazaspiro[3.4]octan-1-yl]-3-oxidanylidene-propanenitrile(Non-covalent)

FHX.1: 19 residues within 4Å: Chain A: L.19, G.20, K.21, G.22, G.25, S.26, V.27, A.44, K.46, V.75, M.93, E.94, Y.95, L.96, R.144, N.145, L.147, A.157, D.158 11 PLIP interactions: 11 interactions with chain A Hydrophobic interactions: A:V.27, A:A.44, A:L.147, A:L.147, A:A.157 Hydrogen bonds: A:G.22, A:V.27, A:E.94, A:L.96 Water bridges: A:N.23, A:K.46

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Noji, S. et al., Discovery of a Janus Kinase Inhibitor Bearing a Highly Three-Dimensional Spiro Scaffold: JTE-052 (Delgocitinib) as a New Dermatological Agent to Treat Inflammatory Skin Disorders. J.Med.Chem. (2020)

Release Date

2020-06-24

Peptides

Tyrosine-protein kinase JAK3: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Tyrosine-protein kinase JAK3